Literature DB >> 16877182

Complementary and alternative medicine use and quality of life in patients with primary brain tumors.

Terri Armstrong1, Marlene Z Cohen, Kenneth R Hess, Rochelle Manning, Eva Lu T Lee, Geline Tamayo, Karen Baumgartner, Sur J Min, Alfred Yung, Mark Gilbert.   

Abstract

This study explored the use of complementary and alternative medicine (CAM) approaches and their relationship with demographic and disease characteristics and quality of life (QOL) in the primary brain tumor (PBT) population. One hundred one PBT patients were enrolled in this study. The results showed that 34% of patients reported using CAM. Forty-one percent reported using more than one type of CAM. The average cost of each CAM used per month was 69 dollars, with 20% of patients spending more than 100 dollars per month. The majority (74%) reported that their physicians were unaware of their use of CAM. Data analysis found a higher performance status to be the only factor significantly related to use of CAM therapy (P < 0.005). There was no difference in patient report of QOL between users and nonusers of CAM therapies. The high number of patients who do not report CAM use has potential implications for evaluation of symptoms and response to therapy in this population. This may be especially relevant in those patients with higher functional status participating in clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 16877182     DOI: 10.1016/j.jpainsymman.2006.02.015

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  14 in total

Review 1.  Polypharmacy in older adults with cancer.

Authors:  Ronald J Maggiore; Cary P Gross; Arti Hurria
Journal:  Oncologist       Date:  2010-04-24

Review 2.  Systematic review of supportive care needs in patients with primary malignant brain tumors.

Authors:  Elizabeth Ford; Susan Catt; Anthony Chalmers; Lesley Fallowfield
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

3.  Complementary and alternative medicine use among US cancer survivors.

Authors:  Gabriella M John; Dawn L Hershman; Laura Falci; Zaixing Shi; Wei-Yann Tsai; Heather Greenlee
Journal:  J Cancer Surviv       Date:  2016-02-26       Impact factor: 4.442

4.  Survivorship care planning and implementation in neuro-oncology.

Authors:  Heather Leeper; Kathrin Milbury
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

Review 5.  The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors.

Authors:  Roy E Strowd; Stuart A Grossman
Journal:  Curr Treat Options Oncol       Date:  2015-08

6.  Complementary and alternative medicine use in glioma patients in France.

Authors:  Emilie Le Rhun; Patrick Devos; Véronique Bourg; Amélie Darlix; Véronique Lorgis; Guido Ahle; Mathieu Boone; Luc Taillandier; Elsa Curtit; Louis Gras; Christine Lebrun Frenay; Dorothee Gramatzki; Carole Ramirez; Nicolas Simon; Michael Weller
Journal:  J Neurooncol       Date:  2019-10-21       Impact factor: 4.130

7.  Quality of Life and Patterns of Use of Complementary and Alternative Medicines Among Glioma Patients.

Authors:  Ketty Mobed; Raymond Liu; Susan Stewart; Margaret Wrensch; Lucie McCoy; Terri Rice; Michael Prados; Susan Chang
Journal:  J Support Oncol       Date:  2009 Nov-Dec

Review 8.  Use of complementary and alternative medical therapy by patients with primary brain tumors.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

Review 9.  Quality of life in adults with brain tumors: current knowledge and future directions.

Authors:  Raymond Liu; Margaretta Page; Karla Solheim; Sherry Fox; Susan M Chang
Journal:  Neuro Oncol       Date:  2008-11-10       Impact factor: 12.300

10.  Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers.

Authors:  Kathrin Milbury; Jing Li; Shiao-Pei Weathers; Smitha Mallaiah; Terri Armstrong; Yisheng Li; Eduardo Bruera; Lorenzo Cohen
Journal:  Neurooncol Pract       Date:  2018-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.